Biotech Investor Adds Million as Krystal Biotech Revenue Rises
A major biotech investor is stepping up its bet on Krystal Biotech as the company posts robust 2025 revenue. This mov...
This article explains the data types used in index level calculations, from price data to breadth indicators, and how each input influences the final level.
28,296 articlesA major biotech investor is stepping up its bet on Krystal Biotech as the company posts robust 2025 revenue. This mov...
AI hype promises a smarter tomorrow, but the costs show up in everyday life—higher bills, stressed sleep, and tougher...
Palantir shares cooled in late June as investors weigh AI-led growth against valuation. Analysts remain divided, with...
Moderna surged on pandemic-era demand. But what comes next? This piece examines why some investors are wary, what a t...
Investors weighed the promise of Milestone Pharmaceuticals against the realities of a high-stakes biotech market. Thi...
Meta Platforms shares slid in early trading as investors weighed analyst comments and evolving ad trends. This articl...
When headlines scream, your wallet shouldn’t follow blindly. This guide shows how to filter hype from facts, using pr...
Nvidia’s quarterly print arrives amid an AI demand cycle that remains uneven. Analysts say nvidia earnings don’t matt...
In 2026, one AI-focused stock has become the darling of bulls and analysts alike. This article dives into the reasons...
Palantir’s AI-enabled analytics engine has fueled growth, but the stock faces multiple headwinds. This article lays o...
OpenAI is moving toward a potential trillion-dollar IPO, with confidential SEC filings reportedly underway and a Sept...
Private AI leaders OpenAI and Anthropic see valuations near $1 trillion as investors chase growth. A cooling IPO wind...